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INTRODUCTION
Endocrine therapy is a standard treatment option in post-
menopausal women with hormone receptor-positive advanced 
breast cancer and has been preferred due to its generally favor-
able toxicity profiles. Several endocrine therapy agents with 
different mechanisms of actions are currently available, includ-
ing the selective estrogen receptor modulators tamoxifen and 
toremifene, the non-steroidal aromatase inhibitors anastrozole 
and letrozole, and the steroidal aromatase inactivator exemes-
tane.
Fulvestrant is a potent estrogen receptor (ER) antagonist 
with a novel mechanism of action. Due to its steroidal struc-
ture, fulvestrant completely inhibits ER signaling by blocking 
and degrading the ER protein [1]. In contrast to tamoxifen, 
fulvestrant has no demonstrable agonist activity [2]. Further-
more, preclinical studies have shown a lack of cross-resistance 
between fulvestrant and tamoxifen [3].
Clinical trials of fulvestrant in postmenopausal women with 
hormone receptor-positive advanced breast cancer have found 
that fulvestrant was at least as effective as anastrozole in tamox-
ifen-resistant patients [4,5] and was at least as effective as ex-
emestane in patients previously treated with non-steroidal aro-
matase inhibitors [6]. Additionally, several retrospective studies 
have found that fulvestrant is effective and tolerated in post-
menopausal women with ER-positive advanced breast cancer 
[7-9]. However, little is known about the efficacy and safety 
profiles of fulvestrant in Asian populations. Therefore, we ret-
rospectively assessed the clinical efficacy and tolerability of 
fulvestrant in Korean patients with hormone receptor-positive 
advanced breast cancer.
METHODS
Patients
A retrospective review of patients with advanced breast can-
cer treated at Asan Medical Center, Seoul, Korea between April 
2007 and October 2009 identified 25 patients, each of whom 
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Purpose: Fulvestrant, a potent estrogen receptor (ER) antagonist 
with a novel mechanism of action, has shown efficacy in pre-
treated patients with advanced breast cancer. We assessed the 
efficacy and tolerability of fulvestrant in Korean postmenopausal 
women. Methods: Of the 25 candidates identified at Asan Medi-
cal Center, Seoul, Korea, six were deemed ineligible due to inad-
equate baseline and follow-up imaging. The 19 patients included 
in this retrospective analysis received the approved dose of fulves-
trant (250 mg intramuscular injection, once per month) as sec-
ond- (n=8), third- (n=7), or fourth-line (n=4) endocrine therapy. 
Results: At a median follow-up of 7.4 months (range, 1.2-34.8 
months), the 19 patients received a median of four cycles (range, 
1-34 cycles) of fulvestrant. Median time to progression was 5.5 
months (95% confidence interval [CI], 0.4-10.7 months), and me-
dian overall survival was 17.9 months (95% CI, 2.7-33.1 months). 
Among 17 evaluable patients, one (5.3%) achieved a partial re-
sponse, 10 (52.6%) showed stable disease, and six (31.6%) showed 
progressive disease. The clinical benefit rate was 26.3%. Four 
patients (21.1%) reported adverse events, but all were grade 1 or 
2. Conclusion: Fulvestrant was effective and well tolerated in patients 
with advanced breast cancer who had been previously treated with 
several lines of endocrine and chemotherapeutic agents.
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received at least one dose of fulvestrant. Data regarding base-
line characteristics, previous treatments, response to prior en-
docrine therapy and survival were obtained by reviewing pa-
tient’s medical records. However, six patients were excluded 
due to inadequate baseline and/or follow-up imaging assess-
ment, which may have biased the results. Hormone receptor 
status was assessed immunohistochemically. Human epider-
mal growth factor receptor 2 (HER2/neu) was considered pos-
itive if immunoreactivity was 3+ or unequivocal amplification 
was demonstrated by fluorescence in situ hybridization (FISH). 
This study was approved by the Asan Medical Center Institu-
tional Review Board (  2006-0449  ).
Treatment and response assessment
Fulvestrant (250 mg) was injected intramuscularly into the 
buttock every 4 weeks until disease progression. During the 
fulvestrant treatment period, patients underwent a physical 
examination and laboratory tests, including complete blood 
counts and chemistry every month and an imaging evaluation, 
such as computed tomography or magnetic resonance imaging 
every 2-3 months or whenever disease progression was clini-
cally suspected. Response was assessed using the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [10]. 
Fulvestrant was deemed to show clinical benefits if patients 
achieved complete response (CR), partial response (PR), or 
stable disease (SD) that was maintained for at least 6 months. 
Adverse events were graded according to the NCI-CTCAE 
version 3.0 [11]. 
Statistical analysis
Time to progression (TTP) was defined as the time from the 
start of fulvestrant treatment to disease progression or death 
from any cause or was censored at last follow-up visit. Overall 
survival (OS) was defined as the time from the start of fulves-
trant treatment to death from any cause or was censored at the 
time of the last follow-up visit in patients who survived. Surviv-
al probability was estimated using the Kaplan-Meier method. 
The log-rank test was used to assess the association between 
survival outcomes and patient baseline characteristics. Hazard 
ratios (HR) and 95% confidence intervals (CIs) were estimated 
using the Cox proportional hazard regression model. A two-
sided p<0.05 was considered statistically significant. All sta-
tistical analyses were performed using SPSS version 18.0 (SPSS 
Inc., Chicago, USA). 
RESULTS
Patient characteristics
The baseline characteristics of the 19 patients included in 
this analysis are summarized in Table 1. The median patient 
age was 55 years, and all were postmenopausal. The most com-
mon metastatic site was bone (n=13, 68.4%), and 11 (57.9%) 
patients had visceral organ involvement. Patients had been pre-
viously treated with a median of two (range, 1-3) endocrine 
therapy regimens, and 18 (94.7%) were treated with letrozole. 
Tamoxifen was administered to two patients in a palliative set-
ting, but had already been used in 15 patients as an adjuvant 
treatment for early breast cancer. Two patients had received 
gonadotropin releasing hormone agonist (GnRH-agonist) as 
they were premenopausal. The clinical benefit of prior endo-
crine therapy, defined as achievement of CR, PR, or SD for at 
least 6 months, was observed in 13 (68.4%) patients. Prior to 
fulvestrant, 10 (52.6%) patients received palliative chemother-
apy, with all 19 patients receiving a median of one (range, 0-6) 
prior regimens. Seven (36.8%) patients underwent radiother-
apy for recurrent or metastatic disease. Details regarding base-
line characteristics and treatment outcomes are presented in-
dividually in Table 2. Almost half of these patients were unfit 
or refused further chemotherapy when they were enrolled. In 
subset of hormone receptor and HER2/neu positive compris-
ing 5-10% of whole breast cancer population, combined use of 
endocrine and HER2 target agent is promising and effective at 
the moment. In practice, trastuzumab is reimbursed in Korea 
only when it is used in combination with taxane in first line of 
metastatic setting or after progression beyond anthracyclines 
Table 1. Baseline characteristics of patients (n=19) 
Characteristics Median (range) No. (%)
Age (yr) 55 (40-71)
Histology
   Invasive ductal carcinoma
   Invasive lobular carcinoma
   Mucinous carcinoma
 
 14 (73.7)
   4 (21.0)
 1 (5.3)
ECOG performance status
   0-1
   2
 
 16 (84.2)
   3 (15.8)
Hormone receptor status
   ER+, PR +
   ER+, PR-
   ER-, PR+
 
 14 (73.7)
   4 (21.0)
 1 (5.3)
HER2/neu status
   Positive*
   Negative
 
 10 (52.6)
   9 (47.4)
Visceral involvement
   Yes
   No
 
 11 (57.9)
   8 (42.1)
Measurable disease
   Yes
   No
 
 12 (63.2)
   7 (36.8)
ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor; 
PR=progesterone receptor. 
*Immunoreactivity 3+ or 2+ with unequivocal amplification by fluores-
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and taxane. Out of ten patients with HER2/neu positive disease, 
only two patients had received trastuzumab and taxane in 1st 
line of metastatic breast cancer (Case No. 11 and 16) before ful-
vestrant. The rest were either unfit for combined trastuzumab 
and taxane regimen or refused upfront use of trastuzumab 
monotherapy because of reimbursement issue.
Efficacy
At a median follow-up period of 7.4 months (range, 1.2-34.8 
months), the 19 patients received a median of four cycles (range, 
1-34 cycles) of fulvestrant. The median TTP was 5.5 months 
(95% CI, 0.4-10.7 months) and the median OS was 17.9 months 
(95% CI, 2.7-33.1 months; Figure 1). In patients who received 
fulvestrant as second-line endocrine therapy, the median TTP 
was not reached, and median OS was 15.9 months (95% CI, 
Table 2. Patient characteristics and treatment outcome
Case 
no.
Age  
(yr)
ECOG 
perfor-
mance 
status
Hormone  
receptor status
HER2/neu  
status* Metastasis sites
Prior hormone  
therapy in  
palliative setting
No. of prior 
chemo-
therapy  
in palliative 
setting
Response  
to  
fulvestrant
Time to  
progression 
(mo)
Overall  
survival  
(mo)
  1 47 1 ER+/PR+ Negative Bone, lung,  
lymph nodes
Letrozole 0 PR 5.6 5.6
  2 60 1 ER+/PR+ Negative Lung Letrozole 0 SD 5.5 17.9
  3 55 1 ER+/PR+ Positive Bone, lymph nodes Letrozole 0 SD 5.7 6.5
  4 52 1 ER+/PR+ Positive Bone Tamoxifen, letrozole,  
exemestane
2 SD 22.1 34.8
  5 70 1 ER+/PR- Negative Lung, liver,  
lymph nodes
Letrozole,  
exemestane
4 SD 8.5 9.2
  6 59 1 ER+/PR+ Negative Lung Letrozole,  
exemestane
3 SD 2.9 8.2
  7 71 1 ER+/PR- Positive Bone Letrozole 0 SD 33.0 33.0
  8 46 1 ER+/PR+ Positive Bone Letrozole 0 SD 10.0 21.2
  9 56 1 ER+/PR- Positive Bone, lymph nodes Letrozole 0 SD 13.2 15.9
10 49 1 ER+/PR+ Negative Bone, chest wall Tamoxifen, letrozole 4 SD 3.5 8.0
11 40 2 ER+/PR+ Positive Bone, lung, brain GnRH-agonist 4 SD 1.5 2.8
12 62 1 ER+/PR+ Positive Bone, lung, liver,  
lymph nodes
Letrozole,  
exemestane
0 PD 1.8 22.0
13 53 1 ER+/PR+ Positive Lung, lymph nodes, 
skin
Letrozole,  
exemestane
0 PD 1.1 2.3
14 71 1 ER+/PR+ Negative Lung, lymph nodes Letrozole,  
exemestane
4 PD 2.5 6.6
15 48 1 ER+/PR+ Positive Bone, liver,  
lymph nodes, pleura
Letrozole,  
exemestane,  
megesterol acetate
1 PD 1.8 5.0
16 41 1 ER+/PR+ Positive Lymph nodes GnRH-agonist,  
letrozole, exemestane
4 PD 1.9 7.4
17 60 1 ER+/PR+ Negative Bone Letrozole 0 PD 2.5 4.9
18 67 2 ER+/PR- Negative Bone, lung, liver,  
lymph nodes
Letrozole,  
exemestane
6 Not available 0.4 1.5
19 50 2 ER-/PR+ Negative Bone, lung, skin Letrozole,  
exemestane
6 Not available 1.1 1.2
ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor; PR=progesterone receptor; PR=partial response; SD=stable disease; PD= 
progressive disease; GnRH-agonist=gonadotropin releasing hormone agonist.
*Immunoreactivity 3+ or 2+ with unequivocal amplification by fluorescence in situ hybridization.
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0.0-39.1 months). In patients who received fulvestrant as third- 
or fourth-line treatment, the median TTP was 2.5 months (95% 
CI, 0.9-4.1 months), and the median OS was 22.0 months (95% 
CI, 0.0-46.7 months). Although TTP was significantly longer 
in patients receiving fulvestrant as second-line therapy than in 
those receiving it as third- or fourth-line therapy (p=0.04), OS 
did not differ between these two groups (p=0.87). The response 
to fulvestrant was evaluable in 17 patients (89.5%). One patient 
(5.3%) achieved PR, 10 (52.6%) achieved SD, and six (31.6%) 
showed PD. A clinical benefit (≥SD over 6 months) was achieved 
in five (26.3%) patients. The patient who achieved PR was a 
48-year-old woman with chemotherapy-induced menopause, 
as shown by her last menstrual history and levels of hormones 
such as follicle stimulating hormone (FSH) and estradiol prior 
to the fulvestrant administration. However, during treatment 
with fulvestrant her serum FSH and estradiol profile restored 
to the premenopausal status. Despite this, she showed a stable 
PR for 3 months.
Tolerability
Adverse events were reported by four (21.1%) patients and 
all were grade 1 or 2. Arthralgia, swelling, and myalgia were 
reported in three (15.8%), two (10.5%), and two (10.5%) pa-
tients, respectively. No injection-related adverse events were 
noted.
DISCUSSION
Our retrospective analysis showed that the approved dose 
(250 mg every 4 weeks) of fulvestrant was effective and well 
tolerated in Korean patients with advanced breast cancer who 
had been previously treated with endocrine and chemothera-
peutic agents. All but one patient treated with GnRH agonist 
showed tumor progression during their previous treatment 
with non-steroidal aromatase inhibitors, and the 19 patients 
had received a median of two prior endocrine therapy regi-
mens. Our efficacy results were consistent with the findings of 
previous prospective and retrospective studies [6-9]. We found 
that the objective response rate to fulvestrant was 5.3%, and the 
clinical benefit rate was 26.3%. The median TTP was 5.5 months, 
and the median OS was 17.9 months. In a large randomized 
phase III trial (EFFECT study), which showed that fulvestrant 
and exemestane had similar efficacy in patients with non-steroi-
dal aromatase inhibitor-resistant advanced breast cancer, the 
overall response rate to fulvestrant was 7.4%, the clinical ben-
efit rate was 32.2%, and the median TTP was 3.7 months [6]. 
Previous retrospective reports based on a single-center expe-
rience showed objective response rates ranging from 9.3% to 
21.7%, clinical benefit rates ranging from 38.9% to 69.5%, and 
median TTP ranging from 4 months to 6.4 months [7-9]. There-
fore, our findings suggest that fulvestrant is similarly effective 
in postmenopausal, heavily pretreated Korean women. Although 
11 of the 19 patients in this study received fulvestrant in a third- 
or fourth-line setting, the survival outcomes were better than 
those reported for the EFFECT trial; this may be due to our 
small sample size, ethnic differences, differences in patient de-
mographics, and continued administration of chemotherapy 
after progression while on fulvestrant.
Previous clinical trials have shown that fulvestrant is well 
tolerated, with toxicity profiles similar to those of other endo-
crine therapeutic agents. In contrast to these earlier trials, we 
observed no adverse events associated with the intramuscular 
injection, such as injection-site pain or reactions [4,6,12,13]. All 
adverse events related to fulvestrant were mild and tolerable. 
Although fulvestrant is a novel and potent ER downregula-
tor and has shown comparable outcomes in second- and third-
line settings [6,14], first-line fulvestrant failed to show superi-
ority to tamoxifen [13]. However, a recent multicenter, open-
label, phase II study suggested that high-dose (500 mg once a 
month) fulvestrant may prolong disease control [12]. Despite 
preclinical promises and an ideal mechanism of action, fulves-
trant has shown lower than expected activity in postmenopaus-
al women with advanced breast cancer. Pharmacokinetic and 
pharmacodynamic studies have suggested that the approved 
dose (250 mg) results in a low steady-state concentration and 
insufficient ER downregulation [15]. The efficacy of fulvestrant 
may be enhanced by various doses and schedules, such as a 
loading dose (500 mg on day 0, 250 mg on day 14, thereafter 
250 mg once per month) and higher monthly doses, both of 
which have shown clinically significant outcomes [6,12,16]. The 
therapeutic potential of fulvestrant may therefore be enhanced 
by investigations into its optimal dose and schedule.
Little has been reported to date about the efficacy and safety 
profiles of fulvestrant in Asian patients. In Korea, fulvestrant 
has been approved for postmenopausal women with advanced 
breast cancer who have progressed on tamoxifen or non-steroi-
dal aromatase inhibitors. However, the cost of fulvestrant is not 
covered by national insurance; thus, limiting its use and result-
ing in a lack of data in Korean patients. We found that fulves-
trant was also effective in a premenopausal patient, supporting 
the previous finding that high dose of 750 mg fulvestrant need-
ed to reduce the effects of estrogen in premenopausal women 
with ER-positive breast cancer [17]. Due to the predominance 
of premenopausal disease in Asian populations, in contrast to 
Western countries [18], further clinical trials with fulvestrant 
are required in premenopausal as well as postmenopausal Asian 
women with ER-positive breast cancer.
In conclusion, fulvestrant had modest activity and a favor-FulvestrantinHeavilyPretreatedAdvancedBreastCancer 139
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able safety profile in heavily pretreated Korean postmenopaus-
al women with advanced breast cancer. Although the sample 
size was too small to suggest new findings based on the results, 
our findings provide further evidence for the use of fulvestrant 
in heavily pretreated patients. To improve the management of 
patients with ER-positive advanced breast cancer, further in-
vestigations to assess the optimal dosage of fulvestrant and to 
maximize its therapeutic efficacy in the cascade of endocrine 
therapeutic agents are warranted.
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